This document is a published patent application from the USPTO detailing novel crystalline forms of a specific amine compound, identified as 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N-methylazetidin-3-amine. The application, filed on September 29, 2023, and published as US20260085071A1, includes claims for pharmaceutical compositions containing these crystalline forms and their use in treating various dermatological conditions, including atopic dermatitis, itch, pruritus, and urticaria.

While this is a patent application and not a regulatory rule, it signifies potential new intellectual property in the pharmaceutical space. Companies involved in drug development, particularly for dermatological conditions, should be aware of this filing as it may impact future research, development, and market exclusivity for similar compounds. No immediate compliance actions are required for entities outside of those directly involved in the patent process or those whose existing intellectual property might be affected.